Evaluation of lokivetmab in dogs with atopic dermatitis

Lokivetmab, a caninised monoclonal antibody against interleukin (IL)-31, is an effective treatment for the pruritus associated with canine atopic dermatitis (cAD). The primary objective of the present study was to investigate the efficacy and safety of lokivetmab during long-term treatment defined as at least three consecutive lokivetmab injections in atopic dogs under field conditions. The secondary objective was to assess individual factors influencing treatment outcome and adverse events. Medical records of dogs treated with lokivetmab were reviewed, and owners and/or veterinarians were contacted as needed for follow-up. A decrease of the pruritus Visual Analog Scale (PVAS) score by ≥2 or a PVAS ...

To read the full article you must log in with your EGO codes.

Use your EGO login data to access Vet.Journal

Username

Password Show Password

Remember Me

Sign in with a passkey

Log in

• Forgot your password?
• Forgot your username?

Check who can access Vet.Journal